1887

Abstract

THIS ARTICLE HAS BEEN RETRACTED

Certain genotypes of (HCV) respond less often than others to treatment with interferon (IFN). The mechanisms for this differential response are not known. In this report antiviral effects of IFN-2b on translation were examined in a hepatic cell line using chimeric clones of internal ribosome entry site (IRES) sequences from six different HCV genotypes and the green fluorescence protein (GFP) gene. As a control, IFN action at the level of the IRES was examined in the presence of different cytokines. It was determined that IFN-2b specifically inhibited the translation of GFP mediated by IRES sequences from six major HCV genotypes in a concentration-dependent manner. Other cytokines including tumour necrosis factor alpha, transforming growth factor beta 1, interleukin 1 and interleukin 6 have no inhibitory effect. The inhibition of translation in these experiments was not due to extensive intracellular degradation of IRES-GFP mRNA. These results suggest that the antiviral action of IFN-2b blocks IRES-mediated translation and this effect is the same among HCVs of other genotypes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81132-0
2005-11-01
2024-12-10
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/11/3047.html?itemId=/content/journal/jgv/10.1099/vir.0.81132-0&mimeType=html&fmt=ahah

References

  1. Ali N., Pruijn G. J., Kenan D. J., Keene J. D., Siddiqui A. 2000; Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J Biol Chem 275:27531–27540
    [Google Scholar]
  2. Alter M. J., Kruszon-Moran D., Nainan O. V., McQuillan G. M., Gao F., Moyer L. A., Kaslow R. A., Margolis H. S. 1999; The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562 [CrossRef]
    [Google Scholar]
  3. Brown E. A., Zhang H., Ping L. H., Lemon S. M. 1992; Secondary structure of the 5′ nontranslated regions of hepatitis C virus and pestivirus genomic RNAs. Nucleic Acids Res 20:5041–5045 [CrossRef]
    [Google Scholar]
  4. Bukh J., Miller R. H., Purcell R. H. 1995; Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41–63 [CrossRef]
    [Google Scholar]
  5. Cao Z., Henzel W. J., Gao X. 1996; IRAK: a kinase associated with the interleukin-1 receptor. Science 271:1128–1131 [CrossRef]
    [Google Scholar]
  6. Castet V., Fournier C., Soulier A., Brillet R., Coste J., Larrey D., Dhumeaux D., Maurel P., Pawlostsky J. M. 2002; Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol 76:8189–8199 [CrossRef]
    [Google Scholar]
  7. Chamberlain R. W., Adams N., Saeed A. A., Simmonds P., Elliott R. M. 1997a; Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 78:1341–1347
    [Google Scholar]
  8. Chamberlain R. W., Adams N. J., Taylor L. A., Simmonds P., Elliott R. M. 1997b; The complete coding sequence of hepatitis C virus genotype 5a, the predominant genotype in South Africa. Biochem Biophys Res Commun 236:44–49 [CrossRef]
    [Google Scholar]
  9. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. 1989; Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362 [CrossRef]
    [Google Scholar]
  10. Collier A. J., Tang S., Elliott R. M. 1998; Translation efficiencies of the 5′ untranslated region from representatives of the six major genotypes of hepatitis C virus using a novel dicistronic reporter assay system. J Gen Virol 79:2359–2366
    [Google Scholar]
  11. Daniels H. M., Meager A., Eddleston A. L., Alexander G. J., Williams R. 1990; Spontaneous production of tumor necrosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 335:875–877 [CrossRef]
    [Google Scholar]
  12. Dasgupta A., Das S., Izumi R., Venkatesan A., Barat B. 2004; Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiol Lett 234:189–199
    [Google Scholar]
  13. Dash S., Prabhu R., Hazari S. 7 other authors 2005; Interferons alpha, beta and gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site mediated translation. Liver Int 25:1–15 [CrossRef]
    [Google Scholar]
  14. Dumoulin F. L., Leifeld L., Honecker U., Sauerbruch T., Spengler U. 1999; Intrahepatic expression of interleukin-1beta and tumor necrosis factor-alpha in chronic hepatitis C. J Infect Dis 180:1704–1708 [CrossRef]
    [Google Scholar]
  15. Fried M. W., Shiffman M. L., Reddy K. R. 11 other authors 2002; Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982 [CrossRef]
    [Google Scholar]
  16. Hadziyannis S. J., Sette H. Jr, Morgan T. R. 11 other authors (for the PEGASYS International Study Group) & ; 2004; Peginterferon- α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355 [CrossRef]
    [Google Scholar]
  17. Han J.-Q., Barton D. J. 2002; Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 8:512–525 [CrossRef]
    [Google Scholar]
  18. Honda M., Brown E. A., Lemon S. M. 1996; Stability of a stem–loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA 10:955–968
    [Google Scholar]
  19. Inchauspe G., Zebedee S., Lee D. H., Sugitani M., Nasoff M., Prince A. M. 1991; Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci U S A 88:10292–10296 [CrossRef]
    [Google Scholar]
  20. Kamoshita N., Tsukiyama-Kohara K., Kohara M., Nomoto A. 1997; Genetic analysis of internal ribosome entry site on hepatitis C virus RNA: implication for involvement of the highly ordered structure and cell type-specific transacting factors. Virology 233:9–18 [CrossRef]
    [Google Scholar]
  21. Kato J., Kato N., Moriyama M., Goto T., Taniguchi H., Shiratori Y., Omata M. 2002; Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway. J Infect Dis 186:155–163 [CrossRef]
    [Google Scholar]
  22. Kozak M. 2003; Alternative ways to think about mRNA sequences and proteins that appear to promote internal initiation of translation. Gene 318:1–23 [CrossRef]
    [Google Scholar]
  23. Lau J. Y., Davis G. L., Prescott L. E., Maertens G., Lindsay K. L., Qian K., Mizokami M. 1996; Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seem at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 124:868–876 [CrossRef]
    [Google Scholar]
  24. Liu S., Yu Y., Zhang M., Wang W., Cao X. 2001; The involvement of TNF- α -related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN- β -stimulated human dendritic cells to tumor cells. J Immunol 166:5407–5415 [CrossRef]
    [Google Scholar]
  25. Mahoney K., Tedeschi V., Maertens G., Di Bisceglie A. M., Vergalla J., Hoofnagle J. H., Sallie R. 1994; Genetic analysis of hepatitis C virus in American patients. Hepatology 20:1405–1411 [CrossRef]
    [Google Scholar]
  26. Manns M. P., McHutchison J. G., Gordon S. C. 7 other authors 2001; Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965 [CrossRef]
    [Google Scholar]
  27. Pawlotsky J. M. 2000; Hepatitis C virus resistance to antiviral therapy. Hepatology 32:889–896 [CrossRef]
    [Google Scholar]
  28. Prabhu R., Joshi V., Garry R. F., Bastian F., Haque S., Regenstein F., Thung S., Dash S. 2004; Interferon alpha-2b inhibits negative-strand RNA and protein expression from full-length HCV1a infectious clone. Exp Mol Pathol 76:242–252 [CrossRef]
    [Google Scholar]
  29. Qi Z. T., Kalkeri G., Hanible J., Prabhu R., Bastian F., Garry R. F., Dash S. 2003; Stem-loop structures II-IV of the 5′ untranslated sequences are required for the expression of the full-length hepatitis C virus genome. Arch Virol 148:449–467 [CrossRef]
    [Google Scholar]
  30. Reed K. E., Rice C. M. 2000; Overview of hepatitis C virus genome structure, polyprotein processing and protein properties. Curr Top Microbiol Immunol 242:55–84
    [Google Scholar]
  31. Reynolds J. E., Kaminski A., Carroll A. R., Clarke B. E., Rowlands D. J., Jackson R. J. 1996; Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon. RNA 2:867–878
    [Google Scholar]
  32. Robertson B., Myers G., Howard C. 14 other authors 1998; Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143:2493–2503 [CrossRef]
    [Google Scholar]
  33. Saito I., Miyamura T., Ohbayashi A. 10 other authors 1990; Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87:6547–6549 [CrossRef]
    [Google Scholar]
  34. Saiz J. C., Lopez de Quinto S., Ibarrola N., Lopez-Labrador F. X., Sanchez-Tapias J. M., Rodes J., Martinez-Salas E. 1999; Internal initiation of translation efficiency in different hepatitis C genotypes isolated from interferon treated patients. Arch Virol 144:215–229 [CrossRef]
    [Google Scholar]
  35. Shimazaki T., Honda M., Kaneko S., Kobayashi K. 2002; Inhibition of internal ribosome entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein. Hepatology 35:199–208 [CrossRef]
    [Google Scholar]
  36. Simmonds P. 2004; Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 85:3173–3188 [CrossRef]
    [Google Scholar]
  37. Simmonds P., Mellor J., Sakuldamrongpanich T., Nuchaprayoon C., Tanprasert S., Holmes E. C., Smith D. B. 1996; Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. J Gen Virol 77:3013–3024 [CrossRef]
    [Google Scholar]
  38. Tang S., Collier A. J., Elliott R. M. 1999; Alterations to both the primary and predicted secondary structure of stem-loop IIIc of the hepatitis C virus 1b 5′ untranslated region (5′UTR) lead to mutants severely defective in translation which cannot be complemented in trans by the wild-type 5′UTR sequence. J Virol 73:2359–2364
    [Google Scholar]
  39. Tilg H., Wilmer A., Vogel W., Herold M., Nolchen B., Judmaier G., Huber C. 1992; Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264–274
    [Google Scholar]
  40. Tokita H., Okamoto H., Luengrojanakul P., Vareesangthip K., Chainuvati T., Iizuka H., Tsuda F., Miyakawa Y., Mayumi M. 1995; Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 76:2329–2335 [CrossRef]
    [Google Scholar]
  41. Tsukiyama-Kohara K., Iizuka N., Kohara M., Nomoto A. 1992; Internal ribosome entry site within hepatitis C virus RNA. J Virol 66:1476–1483
    [Google Scholar]
  42. Wang T. H., Rijnbrand R. C., Lemon S. M. 2000; Core protein-coding sequence, but not core protein, modulates the efficiency of cap-independent translation directed by the internal ribosome entry site of hepatitis C virus. J Virol 74:11347–11358 [CrossRef]
    [Google Scholar]
  43. Zeuzem S. 2000; Treatment of chronic hepatitis C virus infection in patients with cirrhosis. J Viral Hepat 7:327–334 [CrossRef]
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.81132-0
Loading
/content/journal/jgv/10.1099/vir.0.81132-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

PDF

Supplementary material 3

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error